GleamWall
中文EN

SDGR Schrodinger, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1490978 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.8%
TTM net income YoY66.3%
TTM EPS YoY67.1%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR—

Margins

Gross margin58.5%
Operating margin-49.6%
Net margin-22.0%
FCF margin-43.4%
EBITDA margin-47.5%

Returns

ROE-19.0%
ROA-9.4%
ROIC (approx.)-108.6%
Asset turnover0.43x

Leverage & solvency

Liabilities / assets50.7%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.90x
Accruals ratio8.4%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$64.49M$58.89M$58.59M$87.23M$54.32M$54.76M$59.55M$88.32M
Cost of revenue$26.24M$26.46M$29.04M$29.94M$26.29M$28.60M$28.43M$24.19M
Gross profit$38.25M$32.43M$29.55M$57.29M$28.04M$26.16M$31.12M$64.13M
R&D expense$34.09M$41.00M$43.82M$41.40M$42.76M$43.14M$45.84M$49.36M
SG&A expense$20.25M$22.71M$22.91M$22.71M$21.70M$25.19M$25.80M$25.78M
Operating income-$26.13M-$41.55M-$48.79M-$17.16M-$45.95M-$52.90M-$50.89M-$20.71M
Pretax income-$37.55M$7.35M-$59.62M$32.97M-$32.63M-$42.89M-$59.78M-$39.25M
Income tax$156,000$1.37M$408,000$462,000$162,000$287,000$28,000$963,000
Net income-$37.71M$5.97M-$60.03M$32.51M-$32.80M-$43.17M-$59.81M-$40.22M
EBITDA-$24.67M-$40.06M-$47.32M-$15.72M-$44.48M-$51.37M-$49.30M-$18.95M
EPS (basic)-0.500.08-0.81—-0.45-0.59-0.82—
EPS (diluted)-0.500.08-0.81—-0.45-0.59-0.82—
Weighted avg. shares (diluted)74.87M75.77M73.99M—73.61M73.43M73.06M—
Balance sheet
Cash & equivalents$246.98M$287.85M$260.25M$230.52M$181.87M$231.98M$337.76M$162.66M
Short-term investments$119.38M$125.89M$138.70M$164.95M$219.11M$230.28M$174.30M$204.80M
Receivables$48.36M$21.39M$27.25M$83.04M$29.38M$10.07M$20.35M$235.69M
Current assets$456.54M$470.48M$463.96M$519.26M$471.72M$514.00M$570.94M$634.99M
PP&E, net$19.18M$19.46M$20.45M$19.46M$20.74M$21.71M$22.94M$24.20M
Goodwill$4.79M$4.79M$4.79M$4.79M$4.79M$4.79M$4.79M$4.79M
Total assets$611.94M$640.39M$634.19M$726.16M$653.66M$688.24M$743.03M$823.23M
Current liabilities$166.29M$173.84M$169.54M$189.14M$145.11M$155.77M$165.47M$191.75M
Total liabilities$310.11M$311.44M$320.64M$362.11M$332.31M$345.37M$369.53M$401.78M
Shareholders' equity$301.83M$328.96M$313.55M$364.05M$321.35M$342.87M$373.50M$421.44M
Cash flow statement
Operating cash flow-$47.58M-$34.07M-$14.83M-$16.09M-$61.87M-$52.20M$144.06M-$31.11M
Capital expenditure$1.29M$362,000$2.51M$41,000$491,000$314,000$596,000$873,000
Free cash flow-$48.87M-$34.43M-$17.34M-$16.13M-$62.36M-$52.51M$143.47M-$31.99M
Investing cash flow$5.94M$58.62M$44.60M$71.41M$11.46M-$55.60M$30.63M$23.48M
Financing cash flow$2.72M$650,000$569,000$197,000$307,000$2.02M$409,000$119,000
Depreciation & amortization$1.46M$1.49M$1.48M$1.44M$1.47M$1.53M$1.59M$1.76M
Stock-based compensation$7.93M$8.79M$9.07M$9.95M$10.85M$10.63M$11.57M$12.48M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.